Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

被引：0
|
作者：
Amir Ansaripour
Carin A. Uyl-de Groot
W. Ken Redekop
机构：
[1] Erasmus University Rotterdam,Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management
来源：
PharmacoEconomics | 2018年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：381 / 382
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China
    Zhang, Huahua
    Zhang, Yandong
    Huang, Chaonan
    Wang, Jiangfeng
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (06) : 569 - 577
  • [32] Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil
    Vernaglia, P. R.
    Cunha, F. M.
    Correa, M.
    Perdicaris, M. R.
    Saggia, M. G.
    Santos, E. A., V
    Nasciben, V. D.
    Pelizon, C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S106 - S106
  • [33] An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
    Chen, Wen
    Jiang, Zefei
    Shao, Zhimin
    Sun, Qiang
    Shen, Kunwei
    [J]. VALUE IN HEALTH, 2009, 12 : S82 - S84
  • [34] Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
    Guan, X.
    Li, H-C.
    Chen, Q-J.
    Hua, B.
    Li, J-J.
    Ma, F.
    Wang, Y-S.
    Xu, H.
    Liu, C.
    Yang, Q.
    Ma, A-X.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S45 - S45
  • [35] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [36] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    [J]. ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [37] Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
    Fonseca Magalhaes Filho, Marcos Aurelio
    Aguiar, Pedro Nazareth, Jr.
    Mascarenhas Neves, Milena Brachmans
    Lopes, Gilberto de Lima, Jr.
    del Giglio, Auro
    [J]. EINSTEIN-SAO PAULO, 2022, 20 : eGS6655
  • [38] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
  • [39] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Gabriella Mariani
    Angelica Fasolo
    Elena De Benedictis
    Luca Gianni
    [J]. Nature Clinical Practice Oncology, 2009, 6 : 93 - 104
  • [40] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
12345